How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

15,009 results for

Systemic Lupus Erythematosus

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Subacute cutaneous lupus erythematosus and systemic lupus erythematosus associated with abatacept (PubMed)

Subacute cutaneous lupus erythematosus and systemic lupus erythematosus associated with abatacept 30167444 2019 02 26 2352-5126 4 7 2018 Aug JAAD case reports JAAD Case Rep Subacute cutaneous lupus erythematosus and systemic lupus erythematosus associated with abatacept. 698-700 10.1016/j.jdcr.2018.03.008 Tarazi Meera M Corporal Michael J. Crescenz VAMC, Philadelphia, Pennsylvania. Department of Dermatology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania (...) School of Medicine, Philadelphia, Pennsylvania. eng Case Reports 2018 08 16 United States JAAD Case Rep 101665210 2352-5126 ANA, antinuclear antibodies CLE, cutaneous lupus erythematosus CTLA-4, cytotoxic T-lymphocyte–associated antigen-4 HCQ, hydroxychloroquine RA, rheumatoid arthritis SCLE, subacute cutaneous lupus erythematosus SLE, systemic lupus erythematosus abatacept drug-induced lupus erythematosus subacute cutaneous lupus erythematosus systemic lupus erythematosus 2018 9 1 6 0 2018 9 1 6 0

Full Text available with Trip Pro

2018 JAAD Case Reports

22. Novel paradigms in systemic lupus erythematosus. (PubMed)

Novel paradigms in systemic lupus erythematosus. The heterogeneity of systemic lupus erythematosus (SLE), long recognised by clinicians, is now challenging the entire lupus community, from geneticists to clinical investigators. Although the outlook for patients with SLE has greatly improved, many unmet needs remain, chief of which is the development of safer and more efficacious therapies. To develop innovative therapies, a far better understanding of SLE pathogenesis as it relates to the array (...) of clinical phenotypes is needed. Additionally, to efficiently achieve these goals, the lupus community needs to refine existing clinical research tools and better adapt them to overcome the obstacles created by the heterogeneity of manifestations. Here, we review progress towards the ultimate goal of safely reducing disease activity and preventing damage accrual and death. We discuss the new classification criteria from the European League Against Rheumatism and American College of Rheumatology, novel

2019 Lancet

23. Bidirectional relationship between systemic lupus erythematosus and non-Hodgkin`s lymphoma: a nationwide population-based study

Bidirectional relationship between systemic lupus erythematosus and non-Hodgkin`s lymphoma: a nationwide population-based study We conducted this nationwide population-based study in Taiwan to investigate whether there is a bidirectional relationship between SLE and non-Hodgkin's lymphoma (NHL).Using the National Health Insurance Research Database of Taiwan, we identified 16 417 patients with new-onset SLE without previous cancer and 25 069 patients with new-onset NHL without previous SLE

2019 EvidenceUpdates

24. Management strategies and future directions for systemic lupus erythematosus in adults. (PubMed)

Management strategies and future directions for systemic lupus erythematosus in adults. Systemic lupus erythematosus (SLE) is an autoimmune disease characterised by the loss of self-tolerance and formation of nuclear autoantigens and immune complexes resulting in inflammation of multiple organs. The clinical presentation of SLE is heterogeneous, can involve one or more organs, including the skin, kidneys, joints, and nervous system, and take a chronic or relapsing and remitting disease course

2019 Lancet

25. Disease Damage Influences Cardiovascular Risk Reclassification Based on Carotid Ultrasound in Patients with Systemic Lupus Erythematosus

Disease Damage Influences Cardiovascular Risk Reclassification Based on Carotid Ultrasound in Patients with Systemic Lupus Erythematosus Composite scores of cardiovascular (CV) risk factors underestimate the CV risk in patients with systemic lupus erythematosus (SLE). Carotid artery ultrasound (US) was found useful in identifying high CV-risk patients with inflammatory arthritis. We assessed the effect of carotid US assessments on the CV risk stratification of patients with SLE.This cross (...) -sectional study included 276 patients with SLE. These indices were measured: lipid profile, Systematic COronary Risk Evaluation (SCORE) risk calculation, and disease activity (SLE Disease Activity Index), severity (Katz), and damage [Systemic Lupus International Collaborating Clinics (SLICC)/American College of Rheumatology Damage Index]. Carotid plaques were assessed by US. A multivariable regression analysis, adjusted for classic CV-related factors, was performed to evaluate how risk reclassification

2019 EvidenceUpdates

26. Trends in Maternal and Fetal Outcomes Among Pregnant Women With Systemic Lupus Erythematosus in the United States: A Cross-sectional Analysis. (PubMed)

Trends in Maternal and Fetal Outcomes Among Pregnant Women With Systemic Lupus Erythematosus in the United States: A Cross-sectional Analysis. Although pregnancy in systemic lupus erythematosus (SLE) carries a high risk for mother and fetus, outcomes may be improving.To assess nationwide trends and disparities in maternal and fetal complications among pregnant women with SLE.Retrospective cohort study.United States, 1998 to 2015.Adult pregnant women with and without SLE who had hospitalizations

2019 Annals of Internal Medicine

27. Genomics of Systemic Lupus Erythematosus: Insights Gained by Studying Monogenic Young-Onset Systemic Lupus Erythematosus. (PubMed)

Genomics of Systemic Lupus Erythematosus: Insights Gained by Studying Monogenic Young-Onset Systemic Lupus Erythematosus. Systemic lupus erythematosus (SLE) is a systemic, autoimmune, multisystem disease with a heterogeneous clinical phenotype. Genome-wide association studies have identified multiple susceptibility loci, but these explain a fraction of the estimated heritability. This is partly because within the broad spectrum of SLE are monogenic diseases that tend to cluster in patients

2017 Rheumatic Diseases Clinics of North America

28. Impact of disease activity on health-related quality of life in systemic lupus erythematosus – a cross-sectional analysis of the Swiss Systemic Lupus Erythematosus Cohort Study (SSCS) (PubMed)

Impact of disease activity on health-related quality of life in systemic lupus erythematosus – a cross-sectional analysis of the Swiss Systemic Lupus Erythematosus Cohort Study (SSCS) To assess the impact of disease activity on health-related quality of life (HRQoL) in systemic lupus erythematosus (SLE).Cross-sectional study of patients included in the Swiss SLE Cohort Study between April 2007 and June 2014. HRQoL outcomes were based on the Medical Outcome Study Short Form 36 (SF-36). Disease (...) component summary (PCS) 43.7 [37.0-52.8] compared to 49.1 [38.4-55.6], respectively (p < 0.05). Increase in SELENA-SLEDAI or increase in PGA were negatively correlated with PCS and/or MCS. After adjusting for gender, age and disease duration, disease activity impacted on both PCS and MCS and all subscales except general health. Active lupus nephritis and musculoskeletal involvement were associated with physical limitations and emotional problems, increased bodily pain and poor social functioning. Low

Full Text available with Trip Pro

2017 BMC immunology

29. Chinese Systemic Lupus Erythematosus Treatment and Research Group Registry IX: Clinical Features and Survival of Childhood-Onset Systemic Lupus Erythematosus in China (PubMed)

Chinese Systemic Lupus Erythematosus Treatment and Research Group Registry IX: Clinical Features and Survival of Childhood-Onset Systemic Lupus Erythematosus in China Approximately 15-20% cases of systemic lupus erythematosus (SLE) are diagnosed in children. There have been a few studies reporting the epidemiological data of pediatric-onset SLE (cSLE) in China, neither comparing the differences between cSLE and adult-onset SLE (aSLE). The aim of this study was to describe the impact of age (...) was the risk factor for organ damage in lupus patients (hazard ratio 0.335 [0.170-0.658], P = 0.001). The survival curves between the cSLE and aSLE groups had no significant difference as determined by the log-rank test (0.557, P = 0.455).cSLE in China has different clinical features and more inflammation than aSLE patients. Damage may be less in children and there is no difference in 5- year survival between cSLE and aSLE groups.

Full Text available with Trip Pro

2017 Chinese medical journal

30. Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus. (PubMed)

Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus. We evaluated the discriminant capacity of the Lupus Low Disease Activity State (LLDAS) in post-hoc analysis of data from the BLISS-52 and BLISS-76 trials of belimumab in systemic lupus erythematosus (SLE).LLDAS attainment, discrimination between belimumab and placebo arms, and the effects in subgroups with high disease activity (...) at recruitment were evaluated at week 52 using appropriate descriptive statistics, χ2 test and logistic regression.At week 52, for belimumab 10 mg/kg, 17.0% and 19.3% of patients who achieved a Systemic Lupus Erythematosus Responder Index-4 also attained LLDAS in BLISS-52 and BLISS-76, respectively. Significantly more patients attained LLDAS on belimumab 10 mg/kg compared with placebo (12.5% vs 5.8%, OR 2.32, p=0.02 for BLISS-52; 14.4% vs 7.8%, OR 1.98, p=0.04 for BLISS-76). In a subgroup analysis

2019 Annals of the Rheumatic Diseases

31. The risk of cardiovascular morbidity and cardiovascular mortality in systemic lupus erythematosus and lupus nephritis: a Danish nationwide population-based cohort study

The risk of cardiovascular morbidity and cardiovascular mortality in systemic lupus erythematosus and lupus nephritis: a Danish nationwide population-based cohort study . To assess the role of LN as a risk factor for myocardial infarction (MI), stroke and cardiovascular mortality (CVM) in patients with SLE.. The study was conducted using individual-level data from multiple nationwide registers. We identified a cohort of patients diagnosed with SLE and further determined if they had a diagnosis

2017 EvidenceUpdates

32. Predictors of Remission and Low Disease Activity State in Systemic Lupus Erythematosus: Data from a multi-ethnic, multinational Latin-American Lupus Cohort. (PubMed)

Predictors of Remission and Low Disease Activity State in Systemic Lupus Erythematosus: Data from a multi-ethnic, multinational Latin-American Lupus Cohort. To determine the predictors of remission and low disease activity state (LDAS) in systemic lupus erythematosus (SLE).Three disease activity states were defined: Remission=SLEDAI=0 and prednisone≤5mg/d and/or immunosuppressants (maintenance dose); LDAS=SLEDAI≤4, prednisone≤7.5mg/d and/or immunosuppressants (maintenance dose); and non

2019 Journal of Rheumatology

33. Achieving Lupus Low Disease Activity State (LLDAS-50) is associated with both reduced damage accrual and mortality in patients with Systemic Lupus Erythematosus. (PubMed)

Achieving Lupus Low Disease Activity State (LLDAS-50) is associated with both reduced damage accrual and mortality in patients with Systemic Lupus Erythematosus. To assess the impact of achieving Lupus Low Disease Activity State (LLDAS-50) on damage accrual and mortality in an inception cohort of patients with Systemic Lupus Erythematosus (SLE).We used data from the Tromsø Lupus Cohort, a longitudinal population-based study of all SLE patients in the 2 northern-most counties in Norway. LLDAS (...) was defined as a) SLEDAI-2K ≤4, with no activity in major organ systems b) no new features of lupus disease activity c) current prednisolone (or equivalent) dose ≤7.5 mg daily, and, d) well tolerated standard maintenance doses of immunosuppressive drugs.A total of 69 patients (33.5%) spent at least half of their follow up time in LLDAS, thus achieving LLDAS-50, and these patients had both significantly better survival and lower risk of developing severe SDI over time. After correcting for age and sex

2019 Arthritis care & research

34. Musculoskeletal Ultrasound in Systemic Lupus Erythematosus: Systematic Literature Review by the Lupus Task Force of the OMERACT Ultrasound Working Group. (PubMed)

Musculoskeletal Ultrasound in Systemic Lupus Erythematosus: Systematic Literature Review by the Lupus Task Force of the OMERACT Ultrasound Working Group. To identify and synthesize the best available evidence on the application of musculoskeletal ultrasound (US) in patients with systemic lupus erythematosus (SLE) and to present the measurement properties of US in different elementary lesion and pathologies.A systematic literature search of PubMed, Embase and the Cochrane Library was performed

2019 Journal of Rheumatology

35. Dietary omega polyunsaturated fatty acid intake and patient-reported outcomes in systemic lupus erythematosus: The Michigan Lupus Epidemiology & Surveillance (MILES) Program. (PubMed)

Dietary omega polyunsaturated fatty acid intake and patient-reported outcomes in systemic lupus erythematosus: The Michigan Lupus Epidemiology & Surveillance (MILES) Program. To examine associations between dietary intake of omega-3 (n-3; generally anti-inflammatory) and omega-6 (n-6; generally pro-inflammatory) fatty acids and patient-reported outcomes in systemic lupus erythematosus (SLE).This study was based on the population-based Michigan Lupus Epidemiology & Surveillance (MILES) Cohort (...) . Estimates of n-3 and n-6 intake were derived from Diet History Questionnaire II items (DHQ II; past year with portion size version). Patient-reported outcomes included self-reported lupus activity (Systemic Lupus Activity Questionnaire/SLAQ). Multivariable regression, adjusted for age, sex, race, and body mass index, was used to assess associations between absolute intake of n-3 and n-6, as well as the n-6:n-3 ratio, and patient-reported outcomes.Among 456 SLE cases, 425 (93.2%) were female, 207 (45.4

2019 Arthritis care & research

36. Relationship between disease activity, organ damage and health-related quality of life measurements assessed with SF-36, EQ-5D, LupusQol and LupusPRO in patients with systemic lupus erythematosus: a systemic review and meta-analysis

Relationship between disease activity, organ damage and health-related quality of life measurements assessed with SF-36, EQ-5D, LupusQol and LupusPRO in patients with systemic lupus erythematosus: a systemic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate

2019 PROSPERO

37. Performance of the 2012 systemic lupus international collaborating clinics classification criteria versus the 1997 American College of Rheumatology Classification Criteria in adult and juvenile systemic lupus Erythematosus. A systematic review and meta-an (PubMed)

Performance of the 2012 systemic lupus international collaborating clinics classification criteria versus the 1997 American College of Rheumatology Classification Criteria in adult and juvenile systemic lupus Erythematosus. A systematic review and meta-an To evaluate the performance in classifying systemic lupus erythematosus by the 2012 Systemic Lupus International Collaborating Clinics criteria (SLICC'12), versus the revised American College of Rheumatology criteria from 1997 (ACR'97 (...) cutaneous lupus in SLICC'12, and the immunologic and hematologic disorder in ACR'97.Based on sensitivity and specificity SLICC'12 is best for adult SLE. Following the view that higher specificity, i.e. avoidance of false positives, is preferable, ACR'97 is best for juvenile SLE even if associated with lower sensitivity. Our results on the contribution of the individual items of SLICC'12 and ACR´97 may be of value in future efforts to update classification criteria.Copyright © 2018 The Authors. Published

Full Text available with Trip Pro

2018 Autoimmunity reviews

38. Correction: Biomarkers of erosive arthritis in systemic lupus erythematosus: Application of machine learning models. (PubMed)

Correction: Biomarkers of erosive arthritis in systemic lupus erythematosus: Application of machine learning models. [This corrects the article DOI: 10.1371/journal.pone.0207926.].

Full Text available with Trip Pro

2019 PLoS ONE

39. [Effects of physical exercise in a population with systemic lupus erythematosus: A systematic review].

[Effects of physical exercise in a population with systemic lupus erythematosus: A systematic review]. This systematic review was aimed at analysing the existing scientific evidence regarding the effects of physical exercise on the symptomatology, disease activity, and fitness level in a population with systemic lupus erythematosus. Following the PRISMA checklist, a search was carried out on PubMed, PEDro, and Sportdiscus databases. The PEDro and MINORS checklists were used in order to identify (...) the methodological quality of the studies selected. A total of 14 studies were found, of which 10 were randomised controlled trials, and 4 were comparative studies. The performance of physical exercise led to significant improvements in fitness and fatigue. No adverse effects were registered. None of the studies found reported positive effects on the disease activity. The obtained results imply that the performance of physical exercise is safe for people with systemic lupus erythematosus, although its benefits

2018 Semergen

40. Fibrous histiocytoma as first presentation in systemic lupus erythematosus and sero-positive Sjögren's syndrome (PubMed)

Fibrous histiocytoma as first presentation in systemic lupus erythematosus and sero-positive Sjögren's syndrome To describe a triad of fibrous histiocytoma, Systemic Lupus Erythematosus and Sero-positive Sjögren's Syndrome.This case was diagnosed first as bilateral fibrous histiocytoma of cheeks, which on further investigations proved to be a triad of Systemic Lupus Erythematosus, Fibrous histiocytoma and Sero-positive Sjögren's Syndrome.Association between fibrous histiocytoma, Systemic Lupus (...) Erythematosus and Sero-positive Sjögren's Syndrome has been known before, but fibrous histiocytoma as first presentation in the triad has not been reported.

Full Text available with Trip Pro

2018 American journal of ophthalmology case reports

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>